Back

The cardiac toll of ibrutinib: exploring atrial fibrillation in treated patients

20 June 2025 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (1) Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Ines Araujo

Centro Hospitalar Universitário Lisboa Norte, Lisbon (Portugal)

64 More presentations in this session

Presentation thumbnail
Reference values of strain-derived myocardial work indices in adult cancer survivors: results from an observational study and comparison with data from the EACVI NORRE population.
Doctor L. Amore (Rome, IT)
Abstract Slides
Presentation thumbnail
Comparative characteristics of anticoagulants used in cancer-associated thrombosis
Doctor V. Petrusheva (Pleven, BG)
Abstract Slides
Presentation thumbnail
Stroke and cancer - investigating the prevalence of fear among the polish population. cross-sectional study.
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
High-sensitivity troponin T as a biomarker of exercise tolerance impairment assessed in CPET and left ventricular function 3 months after adjuvant therapy for breast cancer
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides
Presentation thumbnail
Ibrutinib increases major adverse cardiovascular events through initiation and exacerbation of hypertension
Assistant Professor Y. Chan (Hong Kong, HK)
Abstract Slides

Access the full session

Session thumbnail
Poster session (1)

The Event

Event poster

ESC Cardio-Oncology 2025

20 June 2025 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Cardiotoxicity in ibrutinib-treated patients: incidence, management, and impact on treatment outcomes
thumbnail
Congress Presentation
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis
thumbnail
Congress Presentation
Ibrutinib increases major adverse cardiovascular events through initiation and exacerbation of hypertension

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources